Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)-Reference-Cited by-同舟云学术

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)

Published:2017 Issue:16 Volume:56 Page:2195-2197
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Watanabe Hiromi¹,Ichihara Eiki²,Kano Hirohisa¹,Ninomiya Kiichiro²,Tanimoto Mitsune²,Kiura Katsuyuki¹

Affiliation:

1. Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan

2. Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/56/16/56_8344-16/_pdf

Reference7 articles.

1. 1. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16: 141-151, 2015.

2. 2. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4: 1046-1061, 2014.

3. 3. Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372: 1689-1699, 2015.

4. 4. Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 7: 133-143, 2015.

5. 5. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7: 153, 2007.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring;Frontiers in Oncology;2024-06-24

2. QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review;Clinical Lung Cancer;2024-06

3. Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study;Therapeutic Advances in Medical Oncology;2024-01

4. Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer;Current Treatment Options in Oncology;2023-12

5. Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report;Cardio-Oncology;2023-10-31